Home › Funds › Casdin Capital › NTLA

Casdin Capital position in NTLA

INTELLIA THERAPEUTICS INC · Health Care

Casdin Capital reported holding 355,000 shares of NTLA (INTELLIA THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$6.0M, representing 0.30% of its reported portfolio and ranking #31 among its reported holdings. Casdin Capital has disclosed NTLA holdings in 13 of the last 16 reported quarters, going back to Q3 2022.

Latest position (Q2 2026)355.00K sh
Reported value held$6.01M
Portfolio Weight0.30%
First reportedQ3 2022
Last changeHold
Updated2026-10-05

Last updated: 2026-10-05 · Source: SEC EDGAR Form 13F-HR

How Casdin Capital's NTLA position evolved

Casdin Capital first disclosed a stake in NTLA in Q3 2022 at 295,000 shares (US$16.5M). The position peaked in Q2 2023 at 1,275,000 shares, worth US$52.0M. Across 13 filings, Casdin Capital increased the stake 3 time(s), trimmed it 2 time(s) and left it unchanged 6 time(s). The most recent filing (Q2 2026) shows 355,000 shares valued at US$6.0M. Notable position changes include a 332% increase in Q1 2023 (shares rose 9% over the following quarter), a 97% trim in Q1 2024 (shares fell 19% over the following quarter), a 3900% increase in Q2 2024 (shares fell 8% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2022 295.00K $16.51M New
Q4 2022 295.00K $10.29M Hold
Q1 2023 1.27M $47.52M Add
Q2 2023 1.27M $51.99M Hold
Q3 2023 1.18M $37.25M Reduce
Q4 2023 1.45M $44.21M Add
Q1 2024 50.00K $1.38M Reduce
Q2 2024 2.00M $44.76M Add
Q3 2024 2.00M $41.10M Hold
Q4 2024 2.00M $23.32M Hold
Q1 2025 2.00M $14.22M Hold
Q1 2026 355.00K $4.55M New
Q2 2026 355.00K $6.01M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NTLA and 13F data

NTLA (INTELLIA THERAPEUTICS INC) is a Health Care company. 39 other funds we track also report a position in NTLA — the largest reported positions include ARK Invest (US$285.5M), RA CAPITAL MANAGEMENT, L.P. (US$76.6M), REGENERON PHARMACEUTICALS, INC. (US$62.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NTLA

All NTLA fund holders →

FAQ

How long has Casdin Capital held NTLA?

Casdin Capital has disclosed NTLA holdings in 13 of the last 16 reported quarters, going back to Q3 2022.

What is Casdin Capital's current position in NTLA?

As of Q2 2026, Casdin Capital holds 355.00K shares of NTLA (INTELLIA THERAPEUTICS INC), valued at $6.01M, representing 0.30% of its reported portfolio and ranking #31.

Has Casdin Capital been buying or selling NTLA?

In the latest 13F filing (Q2 2026), Casdin Capital held unchanged its position in NTLA. The position peaked in Q2 2023 at 1.27M shares.

Which other funds hold NTLA?

Other major institutional holders of NTLA include ARK Invest, RA CAPITAL MANAGEMENT, L.P., REGENERON PHARMACEUTICALS, INC., among 39 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.